France / Japan / Canada / United Kingdom / China / India / Croatia / Belgium / Russia / United States / South Korea / /
Currency
USD / EUR / /
Event
FDA Phase / Patent Filing / Dividend Issuance / /
Facility
William Harvey Research Institute / Quantum Genomics’ pipeline / Queen Mary University of London / DRUG PIPELINE / French National Institute of Health / University of Chicago / Mayo Clinic / /
IndustryTerm
pharmaceutical industry / TREATMENT OF HEART FAILURE / in-house products / age / THERAPY FOR HYPERTENSION / therapies for cardiovascular diseases / technology originating / THERAPIES FOR HYPERTENSION / stage pharmaceutical / manufacturing / technology transfer / age groups / large pharmaceutical groups / galenic and pharmaceutical form / pharmaceutical / healthcare / pharmaceutical groups / biopharmaceutical / treatment of hypertension / healthcare authorities / therapeutic solution / /
World Health Organization / National Research Agency / French National Institute of Health / Research Organization / Paris-Sud University / William Harvey Research Institute / European Union / University of London / the University of Chicago / Mannheim Business School / Ecole Nationale / American Heart Association / Strategic Council for Innovation / Executive Committee of Bayer / /
Person
Jean-Philippe Milon / Quantum Genomics Mickael Dubourd / Christophe Dombu / Fabrice Balavoine / Lionel Ségard / Alexandre Persu / Mark Caulfield / Pierre Corvol / Marc Karako / Innovation / John Burnett Jr. / / /
Position
president / Chief Executive Officer / Engineer / Vice President Chemistry / CEO / Executive / one of the founders / Chief Financial Officer / Legal Officer / Chef / CFO of international groups / Vice President Research & Development Fabrice Balavoine / specialist / Secretary General / Vice president Finance / Chief Operating Officer / Chairman / director / Drug Discovery Manager / Executive Vice President / Chief Executive Officer and Board’s Chairman / /